Literature DB >> 12632511

L-forms of H. pylori.

Ke-Xia Wang1, Chao-Pin Li, Yu-Bao Cui, Ye Tian, Qing-Gui Yang.   

Abstract

AIM: To study the occurrence of L-forms of H. pylori infection in patients with peptic ulcers and its association with possible changes of cellular immune function in the patients.
METHODS: Endoscopic biopsy specimens of gastric antrum and gastric corpus were taken from 228 patients with peptic ulcers and inoculated into Skirrow selective medium for H. pylori vegetative forms and special medium for H. pylori L-forms, followed by bacterial isolation and identification. And peripheral venous blood of the patients was taken to detect the percentage of CD3(+), CD4(+) and CD8(+) with biotin-streptavidin (BSA) and the level of IL-2, IL-6 and IL-8 with ELISA.
RESULTS: (1) The detection rates of H. pylori L-forms and vegetative forms in the patients were 50.88 % (116/228) and 64.91 % (148/228) respectively, and the co-infection rate of H. pylori L-forms and vegetative forms was 78.38 % (116/148). To be more exact, the detection rates of H. pylori L-forms in male and female patients were 57.04 % (77/135) and 41.94 % (39/93) respectively, and statistics found significant difference between them (P<0.05). Furthermore, the detection rates of H. pylori L-forms in patients aged 14 years-, 30 years-, 40 years- and 50 years- were 31.91 % (15/47), 42.86 % (24/56), 56.94 % (41/72) and 67.92 % (36/53) respectively, and there was significant difference between them (P<0.01). (2) The percentages of CD3(+), CD4(+), CD8(+), the ratio of CD4(+)/CD8(+), and the level of IL-2, IL-6, IL-8 in H. pylori-positive patients were (52.59+/-5.44) %, (35.51+/-5.74) %, (27.77+/-8.64) %, (1.56+/-0.51), (2.66+/-0.47) mg/L, (108.62+/-5.85) ng/L and (115.79+/-7.18) ng/L respectively, compared with those in H. pylori-negative patients, the percentages of CD3(+), CD4(+) and the ratio of CD4(+)/CD8(+) decreased, but the level of IL-2, IL-6 increased, and the difference was significant (P<0.001-P<0.01). Moreover, the percentages of CD3(+), CD4(+), CD8(+), the ratio of CD4(+)/CD8(+), and the level of IL-2, IL-6, IL-8 in the patients with mixed infection of both H. pylori L-forms and vegetative forms were (51.69+/-5.28) %, (34.75+/-5.89) %, (27.15+/-7.45) %, (1.48+/-0.47), (2.16+/-0.38) mg/L, (119.45+/-5.44) ng/L and (123.64+/-6.24) ng/L respectively, compared with those in patients with simple infection of H. pylori vegetative forms, the percentage of CD4(+), the ratio of CD4(+)/CD8(+) and the level of IL-2 increased, but the level of IL-6 and IL-8 decreased, statistical difference was found between them (P<0.001-P<0.05).
CONCLUSION: L-forms variation often occurs in patients with peptic ulcers who are infected by H. pylori, which is commonly found in male patients and related to ages. The L-forms variation of H. pylori can be an important factor causing disorder of cellular immune function in the patients with peptic ulcers who are infected by H. pylori.

Entities:  

Mesh:

Year:  2003        PMID: 12632511      PMCID: PMC4621575          DOI: 10.3748/wjg.v9.i3.525

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  36 in total

1.  Helicobacter pylori and gastric cancer:current status of the Austrain Czech German gastric cancer prevention trial (PRISMA Study).

Authors:  S Miehlke; C Kirsch; B Dragosics; M Gschwantler; G Oberhuber; D Antos; P Dite; J Läuter; J Labenz; A Leodolter; P Malfertheiner; A Neubauer; G Ehninger; M Stolte; E Bayerdörffer
Journal:  World J Gastroenterol       Date:  2001-04       Impact factor: 5.742

2.  Alcohol as a gastric disinfectant? The complex relationship between alcohol consumption and current Helicobacter pylori infection.

Authors:  H Brenner; G Bode; G Adler; A Hoffmeister; W Koenig; D Rothenbacher
Journal:  Epidemiology       Date:  2001-03       Impact factor: 4.822

3.  Induction, characterisation and pathogenicity in rainbow trout Oncorhynchus mykiss (Walbaum) of Lactococcus garvieae L-forms.

Authors:  L M Schmidtke; J Carson
Journal:  Vet Microbiol       Date:  1999-09-29       Impact factor: 3.293

4.  An evaluative system for the response of antibacterial therapy: based on the morphological change of Helicobacter pylori and mucosal inflammation.

Authors:  M Wen; Y Zhang; N Yamada; T Matsuhisa; N Matsukura; Y Sugisaki
Journal:  Pathol Int       Date:  1999-04       Impact factor: 2.534

Review 5.  Smoking and peptic ulcer in the Helicobacter pylori era.

Authors:  G Parasher; G L Eastwood
Journal:  Eur J Gastroenterol Hepatol       Date:  2000-08       Impact factor: 2.566

6.  [Helicobacter pylori and gastroduodenal disease in our patients: 2-year experience].

Authors:  E Brigić; L Hodzić; M Zildzić
Journal:  Med Arh       Date:  2000

Review 7.  [When is H pylori a cause of duoenal ulcer? Hypersecretion of gastric acid, active duodenitis and reduced bicarbonate secretion are links in the chain].

Authors:  L Olbe; L Fändriks; A C Thoreson; A M Svennerholm; A Hamlet
Journal:  Lakartidningen       Date:  2000-12-13

8.  Clinical and histologic predictors of Helicobacter pylori infection recurrence.

Authors:  A Zullo; V Rinaldi; C Hassan; F Taggi; M Giustini; S Winn; G Castagna; A F Attili
Journal:  J Clin Gastroenterol       Date:  2000-07       Impact factor: 3.062

9.  Diminished Th1-type cytokine production in gastric mucosa T-lymphocytes after H. pylori eradication in duodenal ulcer patients.

Authors:  A Ihan; B Tepes; M Gubina
Journal:  Pflugers Arch       Date:  2000       Impact factor: 3.657

10.  Helicobacter pylori-induced activation of human endothelial cells.

Authors:  M Innocenti; A-C Thoreson; R L Ferrero; E Strömberg; I Bölin; L Eriksson; A-M Svennerholm; M Quiding-Järbrink
Journal:  Infect Immun       Date:  2002-08       Impact factor: 3.441

View more
  1 in total

1.  Determination of the prevalence of Helicobacter heilmannii-like organisms type 2 (HHLO-2) infection in humans and dogs using non-invasive genus/species-specific PCR in Korea.

Authors:  Tae-Ho Chung; Hee-Dong Kim; Young-Sun Lee; Cheol-Yong Hwang
Journal:  J Vet Med Sci       Date:  2013-09-20       Impact factor: 1.267

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.